TY - JOUR
TI - A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
AU - Weisel, K.
AU - Doyen, C.
AU - Dimopoulos, M.
AU - Yee, A.
AU - Lahuerta, J.J.
AU - Martin, A.
AU - Travers, K.
AU - Druyts, E.
AU - Toor, K.
AU - Abildgaard, N.
AU - Lu, J.
AU - Van Droogenbroeck, J.
AU - Geraldes, C.
AU - Petrini, M.
AU - Voillat, L.
AU - Voog, E.
AU - Facon, T.
JO - Clinical Lymphoma Myeloma and Leukemia
PY - 2017
VL - 58
TODO - 1
SP - 153-161
PB - Taylor and Francis Ltd.
SN - null
TODO - 10.1080/10428194.2016.1177772
TODO - bortezomib;  dexamethasone;  lenalidomide;  melphalan;  prednisone;  thalidomide;  antineoplastic agent, Article;  autologous stem cell transplantation;  cancer combination chemotherapy;  cancer survival;  cancer therapy;  Cochrane Library;  Embase;  human;  intention to treat analysis;  low drug dose;  Medline;  meta analysis;  multiple myeloma;  overall survival;  priority journal;  progression free survival;  randomized controlled trial (topic);  sensitivity analysis;  stem cell transplantation;  systematic review;  treatment duration;  cancer staging;  mortality;  multiple myeloma;  publishing;  survival analysis;  treatment outcome, Antineoplastic Agents;  Antineoplastic Combined Chemotherapy Protocols;  Humans;  Multiple Myeloma;  Neoplasm Staging;  Publication Bias;  Survival Analysis;  Treatment Outcome
TODO - In newly diagnosed multiple myeloma (MM), patients ineligible for front-line autologous stem cell transplantation (ASCT), melphalan and prednisone (MP) with thalidomide (MPT) or bortezomib (VMP) are standard first-line therapeutic options. Despite new treatment regimens incorporating bortezomib or lenalidomide, MM remains incurable. The FIRST study demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) for the combination of lenalidomide and low-dose dexamethasone (Rd) until progression vs. MPT in transplant-ineligible ndMM patients. However, to date no head-to-head randomized controlled trials (RCTs) have compared Rd or MPT versus VMP. We conducted a network meta-analysis using RCTs identified through a systematic literature review to evaluate the relative efficacy of Rd versus other regimens on survival endpoints in previously untreated MM patients ineligible for ASCT. In this analysis, Rd was associated with a significant PFS and survival advantage versus other first-line treatments (VMP, MPT, MP), challenging the role of alkylators in this setting. © 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
ER -